Immunology & Autoimmune Deal Benchmarks
Deal terms for rheumatoid arthritis, lupus, IBD, psoriasis, and other autoimmune conditions. Benchmarks derived from 285 verified transactions.
285
Total Deals
$642M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
129
license
116
acquisition
29
collaboration
2
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Kali Therapeutics → Sanofi KT501 | license | $180M | $1.2B | Mar 2026 |
Galapagos → Novartis MOR106 | license | $111M | $1.1B | Mar 2026 |
MorphoSys → Novartis MOR106 | license | $111M | $1.1B | Mar 2026 |
Theravance → Johnson & Johnson TD-1473 | collaboration | $100M | $1.0B | Mar 2026 |
Dice Therapeutics → Eli Lilly DC-806 | acquisition | $2.4B | $2.4B | Mar 2026 |
Nimble Therapeutics → AbbVie IL-23 peptide inhibitor | acquisition | $200M | $200M | Mar 2026 |
Capstan Therapeutics → AbbVie CPTX-2309 | acquisition | $2.1B | $2.1B | Mar 2026 |
EsoBiotec → AstraZeneca ENaBL-T | acquisition | $1.0B | $1.0B | Mar 2026 |
Galapagos/MorphoSys → Novartis MOR106 | license | $111M | $1.1B | Mar 2026 |
MorphoSys → Novartis MOR106 | license | $111M | $1.1B | Mar 2026 |
Benchmark Your Immunology & Autoimmune Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 285 verified immunology & autoimmune transactions.
Run Immunology & Autoimmune Benchmark